Acute kidney injury (AKI) is a common complication of various critical illnesses and shows independent associations with mortality, morbidity, and prolonged hospitalization \[[@B1][@B2][@B3][@B4][@B5]\]. The current standard of the diagnostic criteria for AKI is based on consensus from consortiums such as the AKI Network or Kidney Disease: Improving Global Outcomes (KDIGO) \[[@B6]\]. Their AKI definitions involve increased serum creatinine (SCr) and/or decreased urine output \[[@B5][@B6]\]. This SCr-based standardization provides several merits from both research and clinical aspects by permitting comparative analysis among patients or studies \[[@B1]\]. However, there are some recognized limitations of these SCr-based AKI definitions as outlined below \[[@B2][@B3]\].

The first limitation is that an increase in SCr does not perfectly match with the degree of structural kidney injury. For example, hemodynamic reduction in renal perfusion can cause increasing SCr levels without definite structural renal impairment \[[@B1]\]. In addition, renin angiotensin aldosterone system inhibitors, which are among the first-line antihypertensive medications, can also result in a SCr increase without accompanying structural kidney injury \[[@B7]\]. The second limitation is that kidney injury can occur without an increase in SCr levels. A renal reserve phenomenon is a representative example of this effect \[[@B1]\]. Functionally reserved parts of nephrons substitute for the injured tubules and reduced glomerular filtration rate (GFR), especially in the early phase of the continuous spectrum of renal impairment \[[@B1]\]. This renal reserve phenomenon results in a lag period of about two --- three days after the start of kidney injury until an SCr increase is detected \[[@B1]\]. This delay may lead to loss of the optimal chance for the early detection of structural kidney injury and the immediate start of appropriate treatment \[[@B1]\]. Besides, a low muscle mass, which leads to decreased creatinine production, can also hinder the detection of structural kidney injury, particularly in newborns or premature babies who have only a very small muscle mass \[[@B8]\].

To overcome these well-known limitations of SCr, novel biomarkers for AKI have been diligently explored to date \[[@B2]\]. Within the last two decades, several new renal markers that are measurable in the blood or urine have been proposed, including neutrophil gelatinase-associated lipocalin (NGAL) \[[@B5][@B9][@B10][@B11]\]. NGAL, also known as siderocalin or lipocalin 2, is a 25-kDa protein in the lipocalin family \[[@B5]\]. NGAL exhibits a bacteriostatic function by binding to and sequestering the iron-siderophore complex, which hinders the bacterial utilization of iron \[[@B12]\]. NGAL is slowly and continuously expressed in various human tissues, including the lung, stomach, prostate, uterus, and kidney \[[@B5]\]. However, the kidney shows particularly upregulated NGAL expression after toxic, septic, or ischemic injuries, especially from the collecting duct and the thick ascending limb of the loop of Henle \[[@B2][@B5]\]. Therefore, NGAL is regarded as an early biomarker of renal tubular damage. After the initial insult, its increase can be detected within 3 hours, reaching a peak at about 6--12 hours, and lasts for up to five days \[[@B5]\].

Accordingly, NGAL is one of the most thoroughly and extensively studied renal markers for heterogeneous phenotypes of AKI, including those associated with nephrotoxic and ischemic injuries \[[@B1][@B4][@B11][@B13][@B14]\]. Recently, the field of research related to NGAL has broadened beyond AKI, including investigations of its association with chronic renal diseases such as diabetic nephropathy or various infectious conditions such as urinary tract infection \[[@B2][@B10][@B14]\]. In this issue of *Annals of Laboratory Medicine*, we introduce an original study that evaluated NGAL in febrile urinary tract infection \[[@B9]\]. These trials for marginal expansion of the clinical adaptation of NGAL may solidify the position of NGAL as a promising next-generation biomarker for the early detection of renal impairment beyond AKI \[[@B11]\].
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